Risk stratification models and mutational analysis: Keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour

Author:

Gronchi Alessandro

Funder

Novartis Pharmaceuticals

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference44 articles.

1. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a European region;Cassier;Br J Cancer,2010

2. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial;DeMatteo;Lancet,2009

3. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial;Joensuu;JAMA,2012

4. 4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: soft tissue sarcoma. V.2.2012. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. [accessed September 6, 2012].

5. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up;The ESMO/European Sarcoma Network Working Group;Ann Oncol,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3